Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours pf-07220060 post-dose
Awards & highlights
Study Summary
This trial compares two formulations of a medicine (PF-07220060) and how they are absorbed into the bloodstream. It also looks at the effects of food & Rabeprazole medicine on the uptake of the medicine.
Who is the study for?
Healthy adults aged 18-65 with a BMI of 17.5-30.5 kg/m2 and weight over 50 kg can join this study. They must be in good health as confirmed by medical exams, tests, and have no history of conditions affecting drug absorption or serious diseases like HIV or hepatitis.Check my eligibility
What is being tested?
The trial is testing two different tablet forms of PF-07220060 to see how they are absorbed into the bloodstream, with and without food, and under the influence of Rabeprazole (a proton pump inhibitor).See study design
What are the potential side effects?
Potential side effects aren't specified but may include reactions typical for clinical trials such as nausea, headache, digestive issues or allergic reactions depending on individual tolerance to PF-07220060.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours pf-07220060 post-dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours pf-07220060 post-dose
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time(AUCinf) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations
Maximum Observed Plasma Concentration (Cmax) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations
Secondary outcome measures
AUCinf of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations at a second dose level
AUCinf of PF-07220060 to estimate the effect of a PPI (rabeprazole) on the bioavailability of a PF-07220060 tablet formulation under fasted condition
AUCinf of PF-07220060 to estimate the effect of a PPI (rabeprazole) on the bioavailability of a PF-07220060 tablet formulation under fed condition
+9 moreTrial Design
7Treatment groups
Experimental Treatment
Group I: Treatment G (Cohort 7)Experimental Treatment1 Intervention
Participants will receive PF-07220060 and Rabeprazole tablet by mouth
Group II: Treatment F (Cohort 6)Experimental Treatment1 Intervention
Participants will receive PF-07220060 and Rabeprazole tablets by mouth
Group III: Treatment E (Cohort 5)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth
Group IV: Treatment D (Cohort 4)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth
Group V: Treatment C (Cohort 3)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth
Group VI: Treatment B (Cohort 2)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth
Group VII: Treatment A (Cohort 1)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
PfizerLead Sponsor
4,568 Previous Clinical Trials
10,911,802 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,475 Previous Clinical Trials
8,092,970 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am generally healthy as confirmed by recent medical exams.I do not have any significant ongoing health issues apart from untreated seasonal allergies.I have a condition that might affect how my body absorbs medication.My BMI is between 17.5 and 30.5, and I weigh more than 110 lbs.I have a history of HIV or hepatitis, or I've tested positive for them. Vaccination for hepatitis B is okay.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment A (Cohort 1)
- Group 2: Treatment B (Cohort 2)
- Group 3: Treatment C (Cohort 3)
- Group 4: Treatment D (Cohort 4)
- Group 5: Treatment E (Cohort 5)
- Group 6: Treatment F (Cohort 6)
- Group 7: Treatment G (Cohort 7)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What health risks may be associated with Treatment A (Cohort 1) for patients?
"The clinical data available on Treatment A (Cohort 1) is scarce, resulting in a safety ranking of 1. This assessment was conducted by Power's medical team as this study only constitutes a Phase 1 trial."
Answered by AI
Is this clinical research still open to enrollees?
"Clinicaltrials.gov records indicate that recruitment for this medical trial has ended, with the study being first posted on July 11th 2023 and last edited two weeks later. Despite its inactive status, there are currently 793 other trials actively searching for volunteers."
Answered by AI
Is participation in this research limited to adults under the age of 25?
"This clinical research necessitates participants have ages between 18 and 65. There are 55 trials specifically for minors and 368 studies directed at individuals aged over 65 years old."
Answered by AI
Who qualifies to join this research project?
"This trial is recruiting 84 participants in the 18 to 65 age bracket who are deemed medically fit, as established through physical examination and laboratory tests. Furthermore, these individuals must have a BMI of 17.5-30.5 kg/m2; body weight >50 kg (110 lb) and sign an Informed Consent Document (ICD)."
Answered by AI
Who else is applying?
What site did they apply to?
New Haven Clinical Research Unit
What portion of applicants met pre-screening criteria?
Met criteria
Why did patients apply to this trial?
I am a healthy 60 year old person.
PatientReceived 2+ prior treatments
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger